Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients
Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients
复制标题
DOI：
10.1097/00007890-199807270-00023
复制
发表时间：
1998-07-27
期刊：
影响因子：
6.2
通讯作者：
Burnier, M
中科院分区：
文献类型：
--
作者：
Minghelli, G;Seydoux, C;Burnier, M
背景血管紧张素II受体拮抗剂氯沙坦是一种有效的抗高血压药物，具有独特的促尿酸排泄作用。本研究评价了氯沙坦对10例高血压心脏移植合并高尿酸血症患者的促尿酸排泄作用。按双盲交叉设计，随机分为氯沙坦组和依那普利组，分别给予氯沙坦50 mg，每日1次和依那普利20 mg，每日1次，疗程4周。在整个研究过程中监测诊室血压、血浆尿酸水平和尿尿酸排泄。氯沙坦治疗4周后血尿酸水平明显下降（P
Background. The angiotensin II receptor antagonist losartan is an effective antihypertensive agent with unique uricosuric properties. This study evaluates the uricosuric effects of losartan in 10 hypertensive heart transplant patients with hyperuricemia.Methods. The patients were randomized to receive losartan 50 mg once daily and enalapril 20 mg once daily for 4 weeks according to a double-blind crossover design. Office blood pressure, plasma uric acid levels, and urinary uric acid excretion mere monitored throughout the study.Results. Plasma uric acid levels decreased significantly after 4 weeks of treatment with losartan (P